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Abstract
Background:  The extended tau haplotype (H1) that covers the entire human microtubule-
associated protein tau (MAPT) gene has been implicated in Parkinson's disease (PD). Nevertheless,
controversial results, such as two studies in Greek populations with opposite effects, have been
reported. Therefore, we set out to determine whether the H1 haplotype and additional single
nucleotide polymorphisms (SNPs) included in H1 are associated with PD in a sample of Greek
patients.
Methods: We analysed MAPT haplotypes in cohorts of 122 patients and 123 controls of Greek
origin, respectively. SNP genotyping was performed with Taqman assays and genotyping results
were confirmed by sequencing.
Results: The presence of the H1 haplotype was significantly associated with PD (odds ratio for
H1H1 vs. H1H2 and H2H2: 1.566; 95% CI: 1.137–2.157; P  = 0.006) and remained so after
adjustment for sex. Further analysis of H1 sub-haplotypes with three single nucleotide
polymorphisms (rs242562, rs2435207 and rs3785883) demonstrated no significant association with
PD.
Conclusion: Our data support the overall genetic role of MAPT and the H1 haplotype for PD
susceptibility in Greek patients. However, the previously supported association of H1 sub-
haplotypes with PD could not be confirmed in our study.
Background
Parkinson's disease (PD) is the most common movement
disorder that becomes more prevalent with advanced age
and represents the second most common neurodegenera-
tive disorder after Alzheimer's disease (AD) [1]. PD is
characterized by four cardinal symptoms: resting tremor,
bradykinesia, muscle rigidity and postural instability [2].
The degeneration of the nigrostriatal dopaminergic neu-
rons causes symptoms of PD and one of the main neu-
ropathological features of the disease consists of
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intracellular proteinaceous inclusions called Lewy bodies
[3]. Aggregation and fibrillization of the α-synuclein pro-
tein, which is the main component of Lewy bodies, repre-
sent key events in the pathogenesis of PD,[4] and the
disease is classified as an α-synucleinopathy.
In addition, a disease mechanism based on the protein tau
has been proposed in PD [5,6]. Tau proteins are a group
of phosphorylated neuronal microtubule-associated pro-
teins that bind to microtubules and promote microtubule
assembly and stabilization. They are expressed in neurons
and they are particularly abundant in axons [7]. Due to
the proposed interactions of α-synuclein and tau protein
and their abnormal intracellular aggregation in neurode-
generative diseases,[5,6] the analysis of microtubule-asso-
ciated protein tau (MAPT) gene as a genetic susceptibility
factor for PD has been of interest.
The MAPT gene is encoded on chromosome 17q21 in the
centre of a 900 kb fragment between two extended haplo-
types, H1 and H2, which cover the entire MAPT gene [8].
H1 and H2 haplotypes differ in orientation,[9] and do not
recombine [10]. Chromosome 17q, containing the MAPT
gene, was one of the regions given the highest logarithm
of odds (lod) scores in the genomic screen for PD con-
ducted by Scott et al [11]. The H1 haplotype of the MAPT
gene had already been associated with the pathogenesis of
parkinsonism tauopathies as progressive supranuclear
palsy and corticobasal degeneration [12]. Subsequently,
the question arose whether H1 homozygosity would be
associated with an increased risk of PD as well. So far,
studies, [13-26] have mostly observed an increase in the
frequency of the H1H1 genotype in patients with PD but
they did not always reach levels of statistical significance
(for review see Zabetian et al., 2007) [27].
Originally, genetic analysis in MAPT was done by differen-
tiating between H1 and H2 haplotypes. This has been
done by analyzing an intron 9 insertion/deletion poly-
morphism, with the 238 bp deletion being characteristic
of the H2 haplotype [8]. The H1 haplotype is more prev-
alent in Caucasians [28]. Therefore, sub-haplotype analy-
sis for H1 carriers has been conducted by investigating
several SNPs [16,17,25,27,29-31]. A positive association
between H1 sub-haplotypes and PD was first reported in
Norwegian patients,[30] involving SNPs rs242562 (G/A)
and rs2435207 (G/A). The 'A-A' sub-haplotype for these
SNPs was significantly associated with PD in this Norwe-
gian cohort, while the 'G-A' sub-haplotype for the same
SNPs was significantly represented in cases compared to
controls in a Greek study [16]. However, in another inde-
pendent study in Greek patients a moderate association
with PD was identified for a different SNP, namely
rs3785883 [17].
Since the two previous studies in Greek PD patients gave
conflicting results, [16,17] we sought to provide more
information on whether the H1 haplotype and H1 sub-
haplotypes are associated with PD in this ethnic group of
patients. We tested a cohort of PD patients and controls
from a different site (Athens) of Greece than the previous
two studies which were based on samples from Northern
and Central Greece.
Methods
Subjects
We recruited 122 unrelated sporadic PD patients (mean
age: 64.5 ± 10.7 years, 41% female, mean age of diagnosis:
51.5 years). The patients were of Greek ancestry and were
selected by G.T. from the Department of Neurology, "G.
Gennimatas" General Hospital, Athens, Greece. All
patients had idiopathic PD and did not suffer from other
neurological diseases. The process of sample collection
did not include any intervention that is not part of any
common clinical practice. Idiopathic Parkinson's disease
(PD) was diagnosed according to the criteria of the UK
Parkinson's Disease Society Brain Bank. The use of the
UKPDS standard diagnostic criteria has been shown to
increase diagnostic accuracy reaching levels of up to 90%
[32]. The PD symptoms were quantified by applying Part
III of the Unified Parkinson's Disease Rating Scale
(UPDRS) [33] score. The control group consisted of 123
unrelated individuals (mean age: 63.7 ± 17.2, 33.3%
female) who were of Greek ancestry as well. The control
subjects donated blood during their treatment inAthens
Trauma Hospital KAT, and in the Onassis Cardiac Surgery
Center, Athens, Greece. The ethics review committees of
the hospitals approved the study and written informed
consent was obtained from all subjects.
Selection of polymorphisms
Our primary objective was to select MAPT  polymor-
phisms which were previously suggested to contribute to
the risk of developing idiopathic PD in Greek subjects.
Therefore, we focussed on the H1/H2 insertion/deletion
polymorphism, rs242562, rs2435207, and rs3785883
and their sub-haplotypes, which were associated with PD
in Greek patients [16,17]. Furthermore, we aimed to pro-
vide more data on MAPT variants with a potential func-
tional role on the regulation of MAPT  in tauopathies,
since increased expression of H1 haplotype has been sug-
gested as a mechanism of PD susceptibility [20]. SNP
rs242557 has been implicated as a functional variant
affecting transcriptional activity of tau in patients with
Alzheimer's disease [34].
The SNP rs242557 was reported to be strongly associated
with rs242562 (r2 = 0.96) by Zabetian et al. [27]. Never-
theless, taking into account its potential functional role
we analyzed rs242557 in our study. It turned out thatBMC Neurology 2009, 9:26 http://www.biomedcentral.com/1471-2377/9/26
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rs242557 was in complete LD with rs242562 among our
H1H1 subgroup of patients. The latter SNP is included in
a three-locus clade containing also rs 3785883 and
rs2471738, which has been strongly associated with the
tauopathies in genetic studies [35] and in a quantitive trait
analysis in Alzheimer's disease [34]. The strongest two-
locus haplotype identified having a significant effect on
tau levels in the Alzheimer's disease study was the one
containing both rs242557 and rs 3785883.
Overall, we have analyzed 5 polymorphisms at MAPT
including the H1/H2 polymorphism, rs242562,
rs2435207, rs242557, and rs3785883. We did not geno-
type rs2471738 which is also included in the three-locus
haplotype analysis previously referred, because it is
known that this SNP is in strong LD with rs2435207
according to the study by Zabetian et al. who reported D'
= 0.98 in PD patients and D' = 0.97 in controls [27]. Taken
together we were able to represent the previously referred
two and three-locus functional sub-haplotypes by the
already selected SNPs.
Genetic analysis of H1 and H2 haplotype
Blood samples were drawn for DNA extraction, using the
QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden,
Germany) and following the manufacturer's protocol,
from patients and controls.
The H1/H2 haplotype differentiation was based on the
insertion/deletion polymorphism and has been per-
formed as reported by Baker et al.,[8] with minor modifi-
cations (Table 1).
Further genetic analysis in H1H1 carriers was performed
by genetic determination of rs242562, rs2435207,
rs3785883 and rs242557. The ABI Prism®  7000 SDS
instrument in conjunction with the ABI TaqMan Univer-
sal Master Mix was used to perform the assays obtained
from Applied Biosystems (Applied Biosystems, Foster
City, CA, USA). Data were analyzed using the ABI Prism®
7000 SDS 1.0 Software (Perkin-Elmer, Applied Biosys-
tems Division). Correctness of genotyping results was
confirmed by sequencing on an ABI 3100 automatic
sequencer using the Big-Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, CA,
USA), for SNPs rs242562 and rs2435207. Therefore, spe-
cific fragments involving rs242562 and rs2435207 were
amplified by PCR (Table 1). Prior to sequencing, reaction
mixtures were purified with a PCR Purification Kit (Qia-
gen GmbH, Hilden, Germany). For SNP rs3785883 accu-
racy of genotypes was evaluated by repeated genotyping of
one half of the samples.
Statistical analysis
A χ2-test was used to compare the allele frequency of each
variant with that expected for a population in Hardy-
Weinberg equilibrium. Fisher's exact test was used to com-
pare H1H1, H1H2, and H2H2 genotype distribution
between cases and control.
Odds ratios (OR) were calculated with 95% confidence
intervals (CI) and exact two-sided P-values, using the SPSS
15.0 program for Windows. Logistic regression analysis
was conducted to adjust for sex differences. The same sta-
tistical procedure was used for genetic analysis of SNPs
rs242562, rs2435207 and rs3785883. In addition, the
square of the correlation coefficient (R2) and D' linkage
disequilibrium (LD) was calculated pairwise between H1-
SNPs in cases and control subjects, using Haploview 4.1
[36]. The PHASE 2.0 software [37] was used for estimating
the frequencies of the sub-haplotypes in H1 homozygous
patients and controls. P-values were considered signifi-
cant at P < 0.05.
Results
H1 and H2 haplotype analysis
The MAPT genotype distribution in PD patients and con-
trols is summarized in Table 2. The observed frequencies
do not deviate from those predicted by Hardy-Weinberg
equilibrium (Table 2) and were comparable to those pre-
viously reported in Caucasians [28]. The H1H1 genotype
was significantly associated with PD (OR for H1H1 vs.
H1H2 and H2H2: 1.566; 95% CI: 1.137–2.157; P  =
0.006). After adjustment for sex, the strong association
with H1H1 remained (OR for H1H1 vs. H1H2 and H2H2:
2.105; 95% CI: 1.250–3.546; P = 0.005). Subsequently,
Table 1: PCR-conditions and sequences of H1-SNP-specific primers.
Primer Sequences PCR-conditions
H1 F
H1 R
5'-GGA AGA CGT TCT CAC TGA TCT G-3'
5'-AGG AGT CTG GCT TCA GTC TCT C-3'
95°C 5 min, 35× (95°C 30s, 55°C 30s, 72°C 30s), 72°C 10 min
rs242562 F
rs242562 R
5'-GGC GAT TCC GCT GAG TCA CC-3'
5'-GGC CCT GCT GGA GTC AAG AG-3'
95°C 5 min, 35× (95°C 30s, 62°C 30s, 72°C 30s), 72°C 10 min
rs2435207 F
rs2435207 R
5'-CTG AGG GCC GTC ACT GTC TG-3'
5'-CCT CAA GCC CAT TCT CTG AC-3'
95°C 5 min, 35× (95°C 30s, 58°C 30s, 72°C 30s), 72°C 10 min
F, forward; R, reverse; SNP, single-nucleotide polymorphisms.BMC Neurology 2009, 9:26 http://www.biomedcentral.com/1471-2377/9/26
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we determined H1 sub-haplotypes in individuals carrying
the H1H1 genotype, in the cohort of patients (n = 84) and
controls (n = 63) of our study, respectively. These results
are summarized in Table 3. SNP rs242557 was in com-
plete LD with rs242562 among our H1H1 subgroup of
patients, therefore this SNP was discarded from further
results analysis. The genotype and allelic distributions
were also in Hardy-Weinberg equilibrium for PD patients
and controls. Fisher's exact test P-values did not reveal any
association between the rs242562, rs2435207, rs3785883
SNPs and PD. LD (calculated as D' and R2) among H1-
SNPs were similar in cases and controls, with the excep-
tion of D' = 0.76 between rs3785883 and rs 2435207 in
cases, which was also greater than the D' reported in pre-
vious studies [25,27] between these two SNPs (Table 4).
We also examined the distribution of H1 sub-haplotypes
which were compiled as combinations of the three SNPs.
This analysis did not reveal any significant difference in
sub-haplotypes involving SNPs rs242562 (G/A) and
rs2435207 (G/A) between cases and controls (Table 5), as
previously reported [16,30]. Finally, we estimated the
effect of the rest two- and three-locus sub-haplotypes
defined by SNPs rs242562, rs2435207 and rs 3785883,
but the results showed no association with PD (data not
shown).
Discussion
Our results confirm that the distribution of the H1 haplo-
type of MAPT  is an important risk factor of PD. Ôwo
meta-analyses of studies on this subject supported the
hypothesis that the H1 haplotype may confer susceptibil-
ity to PD,[18,38] and also recent PD genetic association
studies with a large sample size observed a significantly
greater frequency of the H1 haplotype in PD cases com-
pared to control subjects [27,29,31,39]. Reasons for stud-
ying the relationship between H1 haplotype and PD were
i) the proven increased transcriptional activity of H1 com-
pared to H2,[20] suggesting a possible mechanism of PD
susceptibility, since overexpression of transgenic tau has
been found to cause neuronal death in Drosophila with-
Table 2: MAPT genotype frequencies in Parkinson's Disease.
Genotype % H1H1 vs. H1H2 and H2H2
H1H1 H1H2 H2H2 HWE
P-value
OR 95% CI P value
% cases (n = 122) 68.9 27.9 3.3 0.971 1.566 1.137–2.157 0.006
% controls (n = 123) 51.2 45.5 3.3 0.128 - - -
HWE, Hardy-Weinberg equilibrium; P-value, two-sided exact p-value from Fisher's exact test;
OR, odds ratio; 95% CI = 95% confidence interval.
Table 3: SNP1 and 2 genotype frequencies given as number (%).
Cases (n = 84) Controls (n = 63) P value
rs242562*, 5' of exon 1
Genotypic G/G G/A A/A G/G G/A A/A 0.806
27(32.1) 45(53.6) 12(14.3) 23(36.5) 30(47.6) 10(15.9)
Allelic G A G A 0.706
99(58.9) 69(41.1) 76(60.3) 50(39.7)
rs3785883, Intron 3
Genotypic G/G G/A A/A G/G G/A A/A 0.388
53(63.1) 29(34.5) 2(2.1) 35(55.5) 24(38.1) 4(6.4)
Allelic G A G A 0.239
135(80.4) 33(19.6) 94(74.6) 32(25.4)
rs2435207, Intron 4
Genotypic G/G G/A A/A G/G G/A A/A 0.832
34(40.5) 41(48.8) 9(10.7) 28(44.5) 30(47.6) 5(7.9)
Allelic G A G A 0.777
109(64.9) 59(35.1) 86(68.3) 40(31.7)
P-value, two-sided exact p-value from Fisher's exact test.
* rs242557 revealed identical genotypes in casesBMC Neurology 2009, 9:26 http://www.biomedcentral.com/1471-2377/9/26
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out neurofibrillary tangles,[40] and ii) a possible link
between elevated H1 percentages among PD patients and
tau mediated α-synuclein fibrillization,[6] which is
believed to play an important role in the development
and progression of PD. Our findings support this line of
reasoning and provide further evidence for a role of this
genetic variant of MAPT as a risk factor for PD.
Nevertheless, some conflicting findings have previously
been related to varying effects of H1 in different ethnic
populations [17,25]. Our study is the sixth conducted in a
southern European population (3 Greek, 1 Italian, 1
Spanish, 1 Serbian) and the third in a Greek population.
It is worth noting that five of these studies have also con-
firmed an association of haplotype H1 with PD while one
Greek population study [17] failed to demonstrate this
association. Generally, lack of reproducibility among
case-control studies regarding the role of H1H1 genotype
in PD can be explained by two factors. First, small sample
sizes sometimes lead to underpowered studies. This is not
always a satisfactory explanation since the association was
not confirmed in a rather large group (n = 418) of German
origin [25]. Moreover, the relevance of genetic risk factors
could vary between different ethnic populations. The pos-
sibility of ethnic background influence among white Cau-
casians to explain the contradictory results has been
discussed previously [25]. The genetic association
between the overall MAPT locus and PD has been well
established [18,31,41]. Other genes of the MAPT region
either within the MAPT locus (e.g. Saitohin) or within the
extended H1 haplotype (e.g.KIAA1267), have been also
implicated in PD [31,42]. The genetic dissection of the
MAPT locus and its role in PD is still a major challenge,
because of the complexity of this genomic region. The lat-
ter is a result of both the complex haplotype structure and
the fact that the MAPT locus contains other genes which
are yet not fully characterized. Moreover, it is currently
unclear whether the influence of these genes could vary
among different ethnicities due to varying allele and hap-
lotype frequencies within the MAPT locus. Our data con-
tribute to the evaluation of MAPT  in Greek patients
among which the available studies revealed some contra-
dictory results [16,17].
In the previous study in Greek patients a role of gender
effects on the association between MAPT and PD was sug-
gested [16]. The authors found in separate analysis
according to sex a significant association between H1H1
and PD in men but not in women. This could point to a
potential sex specific effect of genetic MAPT variation to
PD susceptibility. However, it may be also related to a
reduced statistical power in subgroup analysis. Hence,
when we performed a separate statistical analysis for men
and women in our cohort we also found a significant
effect in 72 male patients but no significant effect in 50
female patients. In contrast, in logistic regression analysis
we found no significant effect of sex status affecting the
significant association between H1H1 genotype in the
overall cohort. Our latter finding is in agreement with a
large US case-control cohort study that did not support a
sex specific effect [27].
Efforts were made in previous studies to analyze whether
specific genetic variants in MAPT within the H1 haplotype
are responsible for the increased PD risk. Risk variants on
different H1 sub-haplotypes were found to contribute to
population risk for PD. In each case the variant was found
to be a different one: rs242562-rs2435207 G-A sub-hap-
lotype in a Greek population,[16] A-A sub-haplotype for
the same SNPs in a Norwegian population,[30]
rs3785883 in another Greek population,[17] rs7521 and
rs242557 in a Finnish population,[17] rs2471738 in a UK
population [43] and finally a six-SNP sub-haplotype of
H1 (hCV3202946, rs1800547, rs3785883, rs2435207,
rs11568305, rs1078997) in a multicenter study con-
ducted in Europe and North America [31]. On the other
Table 4: LD for H1-SNPs
Cases (n = 84) Controls (n = 63)
D' R2 D' R2
rs242562* vs rs3785883 0.136 0.007 0.005 0.000
rs242562* vs rs2435207 0.361 0.104 0.340 0.094
rs3785883 vs rs2435207 0.761 0.255 0.528 0.183
Linkage Disequilibrium (LD) measured by D' and R2.
* rs242557 revealed identical genotypes in cases
Table 5: Frequencies of sub-haplotypes (H1-SNPs rs242562-rs2435207) in study groups
Sub-haplotype Cases Frequency Controls Frequency P-value OR (95% CI)
G-G-H1 0.482 0.500 0.814 0.960 (0.737–1.250)
G-A-H1 0.107 0.103 1.000 1.025 (0.662–1.586)
A-G-H1 0.167 0.183 0.757 0.940 (0.671–1.316)
A-A-H1 0.244 0.214 0.579 1.103 (0.795–1.532)
P-value, two-sided exact p-value from Fisher's exact test; OR, odds ratio; 95% CI = 95% confidence interval.BMC Neurology 2009, 9:26 http://www.biomedcentral.com/1471-2377/9/26
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hand, Goris et al.,[29] and Winkler et al.,[25] did not find
any association between PD and specific H1 sub-haplo-
types. Taken together, published data failed to identify a
common sub-haplotype within the H1 haplotype so far.
In the case of sub-haplotypes analyses, the problem of sta-
tistical power might become even more important as the
sample sizes are even smaller, since in some studies only
the H1H1 carriers are examined. In this regard, we tried to
add more data to the previous finding [16] in the Greek
population by examining the same sub-haplotypes in the
same ethnic background, but in patients obtained from a
different site and geographic region. Our data reveal an
almost identical percentage of rs242562 and rs2435207
genotypes and haplotypes among H1H1 patients and
controls, showing that the risk does not seem to arise from
one of the two previously reported sub-haplotypes com-
posed by these SNPs. Furthermore, some of the sub-hap-
lotypes defined by SNPs rs242562, rs2435207 rs3785883,
which represented two and three-locus functional sub-
haplotypes for the tauopathies,[35] do not seem to alter
disease risk in Parkinson as it was also shown in other
studies,[25,43] suggesting that Parkinson does not share
the same pathways with the tauopathies.
A limitation of our study results from the small sample
size and limited statistical power. As a consequence we
examined, however, the consistency of our results by gen-
otyping the H1H2 subjects of our cohorts (data not
shown), namely 118 patients and 119 control individuals
as previously suggested [35]. In this analysis we still did
not identify any effect of single SNPs or SNP sub-haplo-
types. In addition, although we used a well established
standardized clinical scoring system for PD diagnosis mis-
classification of PD patients by lack of histological confir-
mation represents a potential other limitation of our
study. Nevertheless, recently it was shown [43] in patho-
logically confirmed PD cases that the association of MAPT
with the disease is chiefly driven by the H1/H2 division
alone, which is in agreement with our results.
Thus, in order to dissect the genetic and molecular basis of
the H1 haplotype in PD, additional studies and in larger
samples are necessary. Nonetheless, since MAPT  gene
alters PD risk, identification of gene-gene or gene-envi-
ronment interactions, contributing to accelerated degen-
eration of the nigrostriatal dopaminergic neurons, should
be explored. Such knowledge about the underlying mech-
anisms could open up new arenas for early diagnostic and
therapeutic interventions in this important neurodegener-
ative disease [44,45].
Conclusion
Our data show strong evidence of an association between
the H1/H1 genotype and PD in Greek population, how-
ever the SNPs rs242562, rs2435207 and rs3785883
within the H1 haplotype do not seem to alter susceptibil-
ity for PD.
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